Short Description
Quantifies ALT activity, a primary biomarker for liver damage.
Development Stage
Research-Grade Protein & Enzyme Assay Development
Description
The ModifiSite™ Alanine Transaminase Assay Kit serves as a primary biomarker for hepatocellular injury, making it indispensable for assessing drug-induced liver injury (DILI) during pre-clinical toxicology. This kinetic assay enables the continuous monitoring of enzyme activity, providing real-time data on the hepatotoxic potential of new chemical entities. Its implementation in safety screening protocols helps reduce late-stage attrition by identifying liver toxicity early in the development process.
Features
Kinetic assay design enables continuous monitoring of enzyme activity; Critical for early-stage hepatotoxicity screening in pre-clinical safety panels.
Process Relevance
Hepatotoxicity Screening (DILI)
Application Stage
Pre-clinical Safety
Applications
Standard assay for hepatotoxicity studies and monitoring liver health.
Qualified With
Internal performance validation using reference standards under defined assay conditions.
Detection Method
Absorbance at 340 nm
Sample Type
Serum, plasma samples
Research Areas
Hepatology; Toxicology
Datasheet